159 related articles for article (PubMed ID: 27703281)
1. Identification of Differentially Expressed Kinase and Screening Potential Anticancer Drugs in Papillary Thyroid Carcinoma.
Zhang H; Gao B; Shi B
Dis Markers; 2016; 2016():2832980. PubMed ID: 27703281
[No Abstract] [Full Text] [Related]
2. Src inhibitors in suppression of papillary thyroid carcinoma growth.
Henderson YC; Toro-Serra R; Chen Y; Ryu J; Frederick MJ; Zhou G; Gallick GE; Lai SY; Clayman GL
Head Neck; 2014 Mar; 36(3):375-84. PubMed ID: 23729178
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profile analyze the molecular mechanism of CXCR7 regulating papillary thyroid carcinoma growth and metastasis.
Zhang H; Teng X; Liu Z; Zhang L; Liu Z
J Exp Clin Cancer Res; 2015 Feb; 34(1):16. PubMed ID: 25887589
[TBL] [Abstract][Full Text] [Related]
4. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.
Schweppe RE; Kerege AA; French JD; Sharma V; Grzywa RL; Haugen BR
J Clin Endocrinol Metab; 2009 Jun; 94(6):2199-203. PubMed ID: 19293266
[TBL] [Abstract][Full Text] [Related]
6. Identification of potential biomarkers and drugs for papillary thyroid cancer based on gene expression profile analysis.
Qu T; Li YP; Li XH; Chen Y
Mol Med Rep; 2016 Dec; 14(6):5041-5048. PubMed ID: 27779685
[TBL] [Abstract][Full Text] [Related]
7. [Management of refractory thyroid cancers].
Schlumberger M
Ann Endocrinol (Paris); 2011 Apr; 72(2):149-57. PubMed ID: 21514562
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide analysis of long noncoding RNA expression profile in papillary thyroid carcinoma.
Lan X; Zhang H; Wang Z; Dong W; Sun W; Shao L; Zhang T; Zhang D
Gene; 2015 Sep; 569(1):109-17. PubMed ID: 26003293
[TBL] [Abstract][Full Text] [Related]
9. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
[TBL] [Abstract][Full Text] [Related]
10. [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].
Zafon C; Obiols G
Endocrinol Nutr; 2009 Apr; 56(4):176-86. PubMed ID: 19627734
[TBL] [Abstract][Full Text] [Related]
11. Identification of Genes Associated with Papillary Thyroid Carcinoma (PTC) for Diagnosis by Integrated Analysis.
Li WB; Zhou J; Xu L; Su XL; Liu Q; Pang H
Horm Metab Res; 2016 Apr; 48(4):226-31. PubMed ID: 26756467
[TBL] [Abstract][Full Text] [Related]
12. BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (review).
Leonardi GC; Candido S; Carbone M; Raiti F; Colaianni V; Garozzo S; Cinà D; McCubrey JA; Libra M
Mol Med Rep; 2012 Oct; 6(4):687-94. PubMed ID: 22858857
[TBL] [Abstract][Full Text] [Related]
13. Receptor for activated protein C kinase 1 (RACK1) is overexpressed in papillary thyroid carcinoma.
Myklebust LM; Akslen LA; Varhaug JE; Lillehaug JR
Thyroid; 2011 Nov; 21(11):1217-25. PubMed ID: 22007921
[TBL] [Abstract][Full Text] [Related]
14. Platelet derived growth factor receptor alpha mediates nodal metastases in papillary thyroid cancer by driving the epithelial-mesenchymal transition.
Ekpe-Adewuyi E; Lopez-Campistrous A; Tang X; Brindley DN; McMullen TP
Oncotarget; 2016 Dec; 7(50):83684-83700. PubMed ID: 27845909
[TBL] [Abstract][Full Text] [Related]
15. Network-based meta-analysis in the identification of biomarkers for papillary thyroid cancer.
Zhao H; Li H
Gene; 2018 Jun; 661():160-168. PubMed ID: 29625265
[TBL] [Abstract][Full Text] [Related]
16. MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma.
Romitti M; Wajner SM; Ceolin L; Ferreira CV; Ribeiro RV; Rohenkohl HC; Weber Sde S; Lopez PL; Fuziwara CS; Kimura ET; Maia AL
Endocr Relat Cancer; 2016 Mar; 23(3):135-46. PubMed ID: 26825960
[TBL] [Abstract][Full Text] [Related]
17. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
[TBL] [Abstract][Full Text] [Related]
18. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
Henderson YC; Fredrick MJ; Clayman GL
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
[TBL] [Abstract][Full Text] [Related]
19. ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compared to that of corresponding normal thyroid tissues.
Kim SW; Kim HK; Lee JI; Jang HW; Choe JH; Kim JH; Kim JS; Hur KY; Kim JH; Chung JH
Endocr Res; 2013; 38(2):89-97. PubMed ID: 23544999
[TBL] [Abstract][Full Text] [Related]
20. Positive Feedback Loops Between NrCAM and Major Signaling Pathways Contribute to Thyroid Tumorigenesis.
Zhang Y; Sui F; Ma J; Ren X; Guan H; Yang Q; Shi J; Ji M; Shi B; Sun Y; Hou P
J Clin Endocrinol Metab; 2017 Feb; 102(2):613-624. PubMed ID: 27732334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
